Metformin (1,1-Dimethylbiguanide) is an AMPK activator with blood-brain barrier permeability. Metformin may improve glycemic control by increasing insulin sensitivity and decreasing intestinal glucose uptake, and is commonly used in type 2 diabetes research.

Metformin-d6 hydrochloride (Metformin-d6 hydrochloride) is a deuterated form of Metformin that can be used to study Metformin metabolism in vivo, and is often used as an internal standard for Metformin.ccc_R08 can be used to study HBV infection.ccc_R08 can be used to study HBV infection.

Metformin hydrochloride (1,1-Dimethylbiguanide hydrochloride) , a widely used anti-diabetic drug, has a potential function as an anti-Y medicine. It inhibits the proliferation of a variety of Y cells including colon, prostate, and etc.

Linagliptin mixture with metformin is used for the treatment of type 2 diabetes.

Metformin glycinate is an AMP-activated protein kinase (AMPK) activator that improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose.

Metformin icosapent is an AMP-activated protein kinase (AMPK) activator that improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose.

Metformin hydroxy analog 2, an oxidation product of the biguanide metformin (1), represents a chemically transformed variant of the original compound, showcasing a modified molecular structure through the process of oxidation.

Metformin embonate is an AMP-activated protein kinase (AMPK) activator that improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose.

Metformin orotate is an AMP-activated protein kinase (AMPK) activator that improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose.

Metformin hydrochloride mixture with sitagliptin phosphate is an AMP-activated protein kinase stimulant. It is also a CD26 antigen inhibitor, Gluconeogenesis inhibitor, and Glucose modulator.

Syrosingopine has selective depleting effect on brain amines is potentiated by combined treatment with disulfiram or fusaric acid, a dopamine beta-hydroxylase inhibitor.

Sitagliptin (MK0431), a new oral hypoglycemic (anti-diabetic drug), is a new dipeptidyl peptidase-4 (DPP-4) inhibitor. This enzyme-inhibiting drug is used either alone or in combination with metformin or thiazolidinedione for treatment of type 2 diabetes mellitus. The drug can competitively inhibit a protein/enzyme and DPP-4, that leads to an incremental amount of active incretins (GLP-1 and GIP), the diminished amount of release of glucagon and increased release of insulin.

LCC-12 FA is a dimer composed of metformin that induces a decrease in the NAD(H) pool by targeting mitochondrial copper(ii).LCC-12 FA reduces inflammation in mouse models of bacterial and viral infections and may be used in the study of metabolic diseases.

HL271, a derivative of metformin, is a potent AMPK activator that increases AMPK phosphorylation. HL271 attenuates aging-associated cognitive impairment.

IM156 (HL156A; HL271 acetate) is a chemical derivative of Metformin. IM156 is a potent and orally active AMPK activator that increases AMPK phosphorylation. IM156 attenuates aging-associated cognitive impairment in animal model [1] [2]. IM156 is a potent oxidative phosphorylation (OXPHOS) inhibitor which is able to be used for the research of solid tumors [3].

Itasetron hydrochloride monohydrate is a potent 5HT-3 receptor antagonist.

BC1618 (2-Propanol, 1-[bis(phenylmethyl)amino]-3-[4-(trifluoromethyl)phenoxy]-) is an orally active Fbxo48 inhibitor that stimulates Ampk-dependent signaling. It promotes mitochondrial fission, promotes autophagy and improves hepatic insulin sensitivity.

LCC-12, a derivative of the biguanide metformin, acts as a copper (II) chelator. It efficiently forms a monomeric bond with copper (II) and at 20 µM, it mitigates hydrogen peroxide-induced oxidation from NADH to NAD+. At a concentration of 10 µM, LCC-12 significantly reduces the secretion of cytokines IL-1β, IL-2, IL-6, IL-8, and TNF-α, along with the downregulation of JAK2, STAT2, and IL-1 receptor-associated kinase 4 (IRAK4) in primary human cytokine-activated monocyte-derived macrophages (MDMs). Additionally, it decreases the presence of CD80+ and CD86+ within these macrophages at 10 µM. When administered at 0.3 mg/kg per day, LCC-12 enhances survival rates in mouse models exposed to sepsis, triggered either by lipopolysaccharide (LPS) or cecal ligation and puncture.

Galegine hydrochloride, a guanidine derivative derived from G. officinalis, plays a role in inducing weight loss in mice and has contributed to the development of biguanides, including metformin and phenformin. This compound stimulates AMPK activation in 3T3-L1 adipocytes, L6 myotubes, H4IIE rat hepatoma, and HEK293 human kidney cell lines. Additionally, galegine hydrochloride exhibits antibacterial properties, particularly demonstrating a minimum inhibitory concentration of 4 mg/L against Staphylococcus aureus strains[1][2].